An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Christine Baudelet
Employment or Leadership Position - Bristol-Myers Squibb
Allen C. Chen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jeffrey S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb